Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Volastra Therapeutics Logo
Volastra Therapeutics Growth Score
55
CB Rank
19022
Heat Score
31
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.
Founded
obfuscation
PrivateSeries A New York, New York, United States11-50 volastratx.com/
Biotechnology
Life Science
Medical
Overview

Volastra Therapeutics
Total Funding
obfuscation
Growth Score
55
Heat Score
31

Total Funding
obfuscation
obfuscation
Series A raised
obfuscation
Growth Score55
-15 pts
in past quarter
Heat Score 31
-11 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Volastra Therapeutics

CB Rank
19022
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.
Founded
obfuscation
PrivateSeries A New York, New York, United States11-50 volastratx.com/
Biotechnology
Life Science
Medical

Funding Rounds

Series A
OBF
in
obfuscation
Venture - Series Unknown
OBF
in
obfuscation
Series A
OBF
in
obfuscation

Key People

Details

Legal Name Volastra Therapeutics, Inc.
Operating Status Active
Company Type For Profit
Founders  Lewis Cantley, Olivier Elemento, Samuel Bakhoum
About the Company
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers by exploiting unique insights into chromosomal instability.
Predictions & Insights

Growth Insight

See this Growth Insight
Volastra Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Key Employee Changes

Products & Services

VLS-1488
An oral small molecule inhibitor of KIF18A targeting chromosomally unstable cancers, currently in Phase 1/2 clinical trials for advanced solid tumors including platinum-resistant ovarian cancer.
Sovilnesib (formerly AMG-650)
An oral small molecule KIF18A inhibitor in clinical development for ovarian cancer, undergoing Phase 1b trials to determine safety, tolerability, and efficacy in platinum-resistant high-grade serous ovarian cancer.

Research & Development

Volastra Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series A - Volastra Therapeutics Logo
Series A - Volastra Therapeutics
—
obfuscation
— Series A
obfuscation
Series A - Volastra Therapeutics Logo
Series A - Volastra Therapeutics
—
obfuscation
— Series A
obfuscation
Series A - Volastra Therapeutics Logo
Series A - Volastra Therapeutics
—
obfuscation
— Series A
obfuscation
Series A - Volastra Therapeutics Logo
Series A - Volastra Therapeutics
—
obfuscation
— Series A
obfuscation
Series A - Volastra Therapeutics Logo
Series A - Volastra Therapeutics
—
obfuscation
— Series A

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series A - Volastra Therapeutics Logo
Series A - Volastra Therapeutics
—
obfuscation
— Series A
obfuscation
Series A - Volastra Therapeutics Logo
Series A - Volastra Therapeutics
—
obfuscation
— Series A
obfuscation
Series A - Volastra Therapeutics Logo
Series A - Volastra Therapeutics
—
obfuscation
— Series A
obfuscation
Series A - Volastra Therapeutics Logo
Series A - Volastra Therapeutics
—
obfuscation
— Series A
obfuscation
Series A - Volastra Therapeutics Logo
Series A - Volastra Therapeutics
—
obfuscation
— Series A

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 7 Board Members and Advisors 2 Contacts 35

Employee Profiles

Board Members and Advisors

News

News and Press

News•Apr 17, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 17, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 17, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jan 9, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

2,863
61.75%
 in past month

IT Spend

$256.4KThis year, Volastra Therapeutics is projected to spend $256.4K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Sustainable Product Development Logo
Sustainable Product Development
90
Graphics Processing Unit (GPU) Logo
Graphics Processing Unit (GPU)
89
Mission Assurance Logo
Mission Assurance
89

Active Website Tech Count

3Volastra Therapeutics is actively using 3 technologies for its website, according to BuiltWith. These include SPF, CommonCrawl Top 5m, and  Person Schema.

Total IP

15The intellectual property of Volastra Therapeutics includes 14 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery. Additionally, Volastra Therapeutics has 1 registered trademark in the 'Pharmaceutical, veterinary and sanitary products' class, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Volastra Therapeutics's headquarters? Volastra Therapeutics is located in New York, New York, United States.Who invested in Volastra Therapeutics? Volastra Therapeutics has 12 investors including Polaris Partners and  Cornell University.When was the last funding round for Volastra Therapeutics? Volastra Therapeutics closed its last funding round on
obfuscation
from a Series A round.Who are Volastra Therapeutics's competitors? Alternatives and possible competitors to Volastra Therapeutics may include IDEAYA Biosciences, Atavistik Bio, and  Revolution Medicines.How much funding has Volastra Therapeutics raised to date? Volastra Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(a349393 1)
|